Previous 10 | Next 10 |
Antengene announces that China's National Medical Products Administration ((NMPA)) has approved the Investigational New Drug ((IND)) application for a Phase III trial to evaluate the safety and efficacy of selinexor (Xpovio) being co-developed by Karyopharm Therapeutics (KPTI) ...
Image source: The Motley Fool. Karyopharm Therapeutics Inc (NASDAQ: KPTI) Q1 2021 Earnings Call May 3, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Karyopharm Therapeutics Inc (KPTI) Q1 2021 Earnings Call Transcr...
Karyopharm Therapeutics Inc. (KPTI) Q1 2021 Results Earnings Conference Call May 03, 2021, 08:30 AM ET Company Participants Ian Karp - Senior Vice President, Investor and Public Relations Richard Paulson - President and Chief Executive Officer Michael Kauffman - Co-Founder, Senior Clinical Ad...
The following slide deck was published by Karyopharm Therapeutics Inc. in conjunction with their 2021 Q1 earnings call. For further details see: Karyopharm Therapeutics Inc. 2021 Q1 - Results - Earnings Call Presentation
Although Karyopharm Therapeutics (KPTI) saw 35% year-over-year growth in its sole product, XPOVIO (selinexor), the company still missed Q1 earnings estimates.Q1 GAAP EPS missed by $0.07 and although it increased 28.2% compared to the prior-year period, revenue missed by $2.4M.In the quarter, ...
Karyopharm Announces the Appointment of Richard Paulson as President and Chief Executive Officer -- Richard Paulson, Recent Chief Executive Officer of Ipsen North America and Former Vice President and General Manager of Oncology at Amgen, Brings Wealth of Commercial Leadership a...
Karyopharm to Report First Quarter 2021 Financial Results on May 3, 2021 -- Conference Call Scheduled for Monday, May 3, 2021, at 8:30 a.m. ET -- PR Newswire NEWTON, Mass. , April 28, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a com...
Karyopharm Announces European Medicines Agency's Validation of its Type II Variation Marketing Authorization Application for NEXPOVIO® (selinexor) in Combination with Velcade® (bortezomib) and Dexamethasone for the Treatment of Adult Patients with Multiple Myeloma - EM...
Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) traded today at $9.34, breaking its 52-week low. So far today approximately 720,000 shares have been exchanged, as compared to an average 30-day volume of 1.9 million shares. Karyopharm Therapeutics Inc is a pharmaceutical company. The...
Karyopharm Announces Publication of Health-Related Quality of Life Outcomes from Phase 3 SEAL Study of Selinexor in Advanced Unresectable Dedifferentiated Liposarcoma in Future Oncology - Treatment with Selinexor Demonstrated Several Potential Clinical Advantages Compared to Pla...
News, Short Squeeze, Breakout and More Instantly...
Karyopharm Therapeutics Inc. Company Name:
KPTI Stock Symbol:
NASDAQ Market:
Karyopharm Therapeutics Inc. Website:
Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024 PR Newswire -- Conference Call Scheduled for Tuesday, August 6, 2024 , at 8:00 a.m. ET -- NEWTON, Mass. , July 31, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasd...
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates PR Newswire Long-Term Follow-Up Data Signal Promising Progression-Free S...
Karyopharm to Participate at the Jefferies Global Healthcare Conference PR Newswire NEWTON, Mass. , May 29, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announ...